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Abstract 
Context: Intramuscular Testosterone undecanoate (TU) depot injection has become a popular preparation for 
the treatment of hypogonadism.  Progressive accumulation of the product occurs with successive injections 
and gradual increment in injection interval is required in most cases to prevent testosterone-induced 
erythyrocytosis. However, the wash-out period of exogenous testosterone after discontinuation of 
intramuscular TU depot injection has not been previously studied. Knowledge of the wash-out period of TU 
is of particular interest in cases of newly diagnosed prostate cancer and for those who plan to start 
spermatogenesis-induction therapy with gonadotropins.  
Patients and design: We performed a retrospective study to investigate the wash-out period of exogenous 
testosterone after discontinuation of TU depot injection in 4 men with congenital hypogonadotrophic 
hypogonadism (HH). TU injections were discontinued in this group of patients in order to allow them to 
enrol in a clinical trial of spermatogenesis-induction therapy.  The time interval for serum testosterone 
concentration to drop below 6nmol/L was examined. 
Results: The rate of decline in serum testosterone (both total and free) levels was surprisingly shallow, with 
these 4 men taking an average of 30 weeks for testosterone level to decline from within the eugonadal range 
(mean total testosterone: 14.7 nmol/L; range: 12.8 - 19.1) to under 6 nmol/L.  
Conclusion: This study demonstrated a potential prolonged washout period among profoundly hypogonadal 
men who had been regularly receiving TU depot injection. Further studies with larger patient cohort are 
required to examine the biochemical and clinical details on the wash-out period among men receiving this 
product.  
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Correspondence 
Intramuscular Testosterone undecanoate (TU) depot 1g (Nebido
®
 or Reandron
®
) is an increasingly popular 
testosterone preparation in view of convenience and pharmacokinetic profile. The datasheet recommends that 
it be given at 10-14 week intervals, except for the first two injections given six week apart.  With a fixed 
dose-interval, accumulation of the product can occur with successive injections, as shown by progressively 
increased area-under-curve for serum testosterone (T) from first to fifth to thirteenth injections
 1-3
. Our own 
practice is to proactively manage the injection-interval over the first 2-3 years of treatment, progressively 
extending it if necessary over successive injections, in order to avoid T-induced erythrocytosis. 
Although the pharmacokinetic profile of TU from single dose to complete washout is well-established from 
phase I and II studies, there are no data on the washout period (time for serum T to return to the pre-
treatment hypogonadal range) for patients in steady-state. i.e. who have been receiving TU for several years 
and whose injection-interval, optimised for the desired trough T and haematocrit, is reasonably consistent 
(±1 week).  However, a study of TU as a potential male hormonal contraceptive found that suppression of 
spermatogenesis could persist for up to 5 months following discontinuation of the hormonal therapy
 4
. This 
led us to suspect that the steady-state washout (SSW) time might be similarly prolonged. Knowledge of SSW 
data might be of particular interest to clinicians under two specific circumstances. First, when newly-
developed high-grade prostate cancer is suspected, or diagnosed. Second, for men with hypogonadotrophic 
hypogonadism (HH) planning to start spermatogenesis-induction therapy with gonadotropins, as they will 
need to convert to indirect androgen replacement through human chorionic gonadotropin (hCG)-stimulated 
endogenous T synthesis. Fortunately, we have yet to encounter the first scenario, but were faced with the 
second during the process of recruitment and randomisation to a phase III clinical trial
 5
.  This trial (NCT 
number: 01709331) investigated the efficacy and safety of MK-8962 (corifollitropin alfa) in combination 
with hCG in adult men with HH who remain azoospermic when treated with hCG alone. 
 We report a series of 4 men with congenital HH (baseline levels of gonadotrophins and testosterone below 
1.5 IU/l and 3nmol/l, respectively), median age 34.5 years (range: 25 - 44) taking an average of 30 weeks 
(range: 20 - 52) for testosterone level to decline from eugonadal range (mean total testosterone 14.7 nmol/l; 
range: 12.8 - 19.1) to <6 nmol/l. All these men had been on steady-state treatment with TU for at least 3 
Page 4 of 9 
 
years, with a median injection-interval optimised at 12 ±1 weeks.  Their clinical characteristics are shown in 
the Supplementary data.  TU injections were discontinued in order to allow these men to enrol in a clinical 
trial of spermatogenesis-induction therapy with an investigational gonadotrophin molecule, for which serum 
T concentration below 6 nmol/l was a prerequisite for enrolment in the active phase of the study
 5
.  As per 
UK clinical trial regulations, these men received no payment for study participation; only reimbursement of 
their reasonable travel expenses. 
Serum T was assayed centrally by Quest Diagnostics (Heston, Middlesex, UK) using a liquid 
chromatography-tandem mass spectrometry method and Thermofinigan analyser (c.v 4.26%).  Sex hormone 
binding globulin (SHBG) and albumin were measured locally by two-site sandwich immunoassay, using 
electro-chemiluminescence technology, and by a dye-binding assay, respectively (both by Roche Modular 
System, Roche Diagnostics, Lewes, UK), enabling free T to be calculated using a mass action formula
 6
.  The 
rate of decline in serum T (both total and free) levels proved to be so shallow (Figure 1) that only two of the 
four men could ultimately be recruited to this study within the permissible time-frame.   
There was no evidence of HH
 
reversal among these men; all being azoospermic at baseline, with consistently 
undetectable gonadotrophins persisting even when serum total and calculated free T concentration had fallen 
unequivocally below the normal adult male reference range.  Testicular volumes also remained <3ml 
throughout this period.  Two subjects exhibited slight “rebound” in serum T levels at one point.  This 
phenomenon was not unknown to us from 10 years’ experience with TU and is consistent with T release 
from intramuscular TU depots not invariably occurring in a completely predictable, linear manner over time.  
Moreover, serum T at any time-point is unlikely to be exclusively derived from the intramuscular depot 
related to the most recent TU injection.  It is likely that some of the circulating serum T is also derived from 
“older” depots.  However, as per study protocol, both patients and their primary care physicians were 
carefully questioned regarding the possibility that they might have briefly used a T shot-acting T product.  
Although we found no evidence whatsoever for this and are confident that it did not occur, the possibility 
cannot be entirely excluded. 
The observation of prolonged wash-out period following discontinuation of TU injections in hypogonadal 
men is of pharmacokinetic interest and has potential clinical implications.  First, the prolonged SSW time for 
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TU injection might impact on the optimisation of spermatogenesis-induction therapy; therapeutic adjustment 
of hCG dose could prove more difficult without knowing the proportion of serum T derived from 
endogenous hCG-driven secretion.  HH men who wish to achieve fertility, but having substantial amounts of 
exogenously-derived T still being released from previous IM depot injections, would thus need to be treated 
pragmatically with the highest dose of hCG, short of causing T-driven erythrocytosis.  Such a regime might 
be less likely to achieve the high intratesticular T levels that are required for optimal Sertoli cell function.   
Second, prolonged male-range T concentrations following discontinuation of TU injections might have 
implications for hypogonadal men diagnosed with high-grade, androgen-sensitive prostate cancer.  Although 
T replacement therapy can be cautiously considered in hypogonadal men previously treated with curative 
intent for low-risk prostate cancer, and without evidence of active disease
 7
, the administration of T to men 
with active prostate cancer has been associated with adverse outcomes.  Hence, most specialists treating a 
man with prostate cancer would aim to achieve complete clearance of T from the circulation as rapidly as 
possible.  Were this to be unachievable due to prolonged T depot-effect, then anti-androgen therapy would 
likely need to be considered.   
The reason for the prolonged circulating total and free T concentrations in these men HH is not readily 
apparent.  Although the individual variance in body composition and adiposity could potentially result in 
delayed testosterone clearance
 8
, SHBG levels remained relatively steady and only began to rise when serum 
total T fell well-within the hypogonadal range.  There was also no evidence of renal or liver dysfunction to 
suggest reduced hepatic or extrahepatic clearance.  On the other hand, genetic polymorphism might 
contribute to inter-individual variability in T clearance and metabolism and a common polymorphism in the 
UGT2B17 gene has been shown to have a modest effect on serum testosterone level following TU therapy
 9 
 
although these men were not tested for this variant.  
In summary, there has hitherto been a general lack of detailed data relating to the wash-out period among 
men receiving steady-state TU.  We have demonstrated for the first time the potential for SSW period among 
men receiving TU injections, with up to 13 months being potentially required for exogenous testosterone to 
be fully-cleared.  Better understanding of the determinants (both genetic and non-genetic) of TU clearance 
might improve the selection of TU dosage and injection intervals.  
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Figure 1 legend. 
Trend of total T (nmol/L) and calculated free T (pmol/L) concentrations for patients A-D.  
X-axis shows the time since discontinuation of TU with 0 indicating the day they received their last TU 
injections. Left Y-axis shows total T concentration and right Y-axis the calculated free T concentration.  
Serum T was assayed centrally by Quest Diagnostics (Heston, Middlesex, UK) using a liquid 
chromatography-tandem mass spectrometry method and Thermofinigan analyser (C.V: 4.26%).  
The data are limited by irregular measurement of serum T concentration; hence the trajectories of the decline 
are less accurate than would have been the case with fixed intervals for blood sampling.  Gonadotrophins for 
all 4 men were <0.5IU/L at each time point of T measurement. 
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Figure 1.The trend of total testosterone (nmol/L) and calculated free testosterone concentration (pmol/L) for patient A-D since the last dose 
of testosterone undecanoate injection. 
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Supplement A 
Patient Characteristics 
Patient Diagnosis 
Genetic 
variants 
Age of 
diagnosis 
(years) 
Age when T commenced (years) 
Pubertal 
induction 
required? 
Age at last 
TU injection 
(years) 
A KS 
 
KAL1 
(W237X) 
hemizygous 
 
22 - Low-dose monthly Sustanon 50mg, age 17-19 years, when he 
was (inappropriately) presumed to have simple pubertal delay. 
- Physiological testosterone replacement commenced from age 
22 with a variety of preparations, most recently TU. 
Yes, absent 
puberty  at 
diagnosis 
43 
B normosmic 
CHH 
none 
identified 
19 -  TU from age 19 years. Yes, absent 
puberty  at 
diagnosis 
24 
C KS PROK2  
(R73C)  
heterozygous 
34 - Mixture of Sustanon 250mg and hCG 1,500 IU, age 34-36 
years; switched to TU from age 37. 
Yes, absent 
puberty  at 
diagnosis 
40 
D KS CHD7 
(M340V)  
heterozygous 
17 - Sustanon 250mg, age 17-18 years, then switched to TU. Yes, absent 
puberty  at 
diagnosis 
27 
 
 
